{
  "pmcid": "PMC12331468",
  "pmid": "40786508",
  "title": "Genetic variants and clinical determinants affecting the response to 5-Fluorouracil-based treatment in Chilean patients with advanced colorectal cancer",
  "overall_score": 0.3798788836962647,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 17,
        "items": [
          {
            "variant": "rs11280056",
            "gene": "TYMS",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "rs11280056",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "In univariate logistic regression, the TYMS 3\u2019UTR 6bp deletion (rs11280056) was associated with a lower risk of gastrointestinal disorders during FP-based chemotherapy. Codominant model: INS/INS vs DEL/DEL OR=0.100, 95% CI 0.004\u20130.710, p=0.045. The deletion allele was described as protective against gastrointestinal adverse reactions.",
              "Sentence": "Genotype DEL/DEL is associated with decreased risk of gastrointestinal disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype INS/INS.",
              "Alleles": "DEL/DEL",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of gastrointestinal disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "INS/INS",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"We identified a protective correlation between the 6bp deletion of the *TYMS* 3\u2019UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.\"",
                "\"Gastrointestinal disorders\n\nTYMS 3\u2019UTR 6bp ins-del (rs11280056)\n\nCodominant | INS/INS | 1.000 | -- | Ref.\n\nINS/DEL | 0.152 | 0.007 \u2013 0.991 | 0.093  \nDEL/DEL | 0.100 | 0.004 \u2013 0.071 | 0.045*\"",
                "\"When analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the *TYMS* 3\u2019UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 \u2013 0.441, p-value =0.005).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11280056",
                "variant_id": "PA166180936",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs11280056",
            "gene": "TYMS",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "rs11280056",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "The TYMS 3\u2019UTR 6bp deletion genotype (rs11280056) conferred protection against hematological adverse reactions. Univariate logistic regression (grouped hematological disorders): codominant model INS/INS vs INS/DEL OR=0.156, 95% CI 0.044\u20130.498, p=0.002; INS/INS vs DEL/DEL OR=0.029, 95% CI 0.004\u20130.182, p=0.001. Dominant model (INS/DEL+DEL/DEL vs INS/INS) OR=0.107, 95% CI 0.030\u20130.303, p<0.0001. Recessive model (DEL/DEL vs INS/INS+INS/DEL) OR=0.075, 95% CI 0.004\u20130.421, p=0.015.",
              "Sentence": "Genotype DEL/DEL is associated with decreased risk of hematological disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype INS/INS.",
              "Alleles": "DEL/DEL",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of hematological disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "INS/INS",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Among the 16 variants analyzed in 82 patients, key findings included: The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036). The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05). The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).\u201d",
                "\u201cWe identified a protective correlation between the 6bp deletion of the TYMS 3\u2019UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.\u201d",
                "\u201cHematological disorders\nTYMS 3\u2019UTR 6bp ins-del (rs11280056)\nCodominant\tINS/INS\t1.000\t--\tRef.\nINS/DEL\t0.156\t0.044 \u2013 0.498\t0.002*\nDEL/DEL\t0.029\t0.004 \u2013 0.182\t0.001*\nDominant\tINS/INS\t1.000\t--\tRef.\nINS/DEL + DEL/DEL\t0.107\t0.030 \u2013 0.303\t<0.0001*\nRecessive\tINS/INS + INS/DEL\t1.000\t--\tRef.\nDEL/DEL\t0.075\t0.004 \u2013 0.421\t0.015*\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11280056",
                "variant_id": "PA166180936",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs11280056",
            "gene": "TYMS",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs11280056",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "When only severe (CTCAE grade III\u2013IV) grouped hematological disorders were considered, the TYMS 3\u2019UTR 6bp deletion (rs11280056) remained associated with a lower risk of severe hematological toxicity. Dominant model: INS/DEL+DEL/DEL vs INS/INS OR=0.098, 95% CI 0.013\u20130.441, p=0.005.",
              "Sentence": "Genotypes INS/DEL + DEL/DEL are associated with decreased risk of severe hematological disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype INS/INS.",
              "Alleles": "INS/DEL + DEL/DEL",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of severe hematological disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "INS/INS",
              "Comparison Metabolizer types": null,
              "Citations": [
                "When analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the *TYMS* 3\u2019UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 \u2013 0.441, p-value =0.005).",
                "The main therapeutic target of 5-FU is the inhibition of the TS enzyme ([Figure 1](#f1)). Among the key genetic variants, the 6bp deletion in the 3\u2019UTR (rs11280056) was associated with a decreased risk of gastrointestinal and hematological ADRs.",
                "Among the 16 variants analyzed in 82 patients, key findings included: The G allele of *GSTP1* (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036). The C allele of *DPYD* (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05). The *TYMS* deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001). On the other hand, the 3R genotype of *TYMS* 5\u2019UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029)."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11280056",
                "variant_id": "PA166180936",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs13181",
            "gene": "ERCC2",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "rs13181",
              "Gene": "ERCC2",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "ERCC2 c.2251A>C (rs13181) C/C genotype was associated with lower risk of gastrointestinal disorders. Codominant model: A/A vs C/C OR=0.100, 95% CI 0.004\u20130.710, p=0.045; A/A vs A/C OR=0.152, 95% CI 0.007\u20130.991, p=0.093.",
              "Sentence": "Genotype C/C is associated with decreased risk of gastrointestinal disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype A/A.",
              "Alleles": "C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of gastrointestinal disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The next stage of analysis involved evaluating the correlation between the polymorphisms in the *TYMS*, *TYMP*, *DPYD*, *GSTP1*, *MTHFR*, *ERCC2*, and *ABC* genes and the risk of ADR of any severity during FU-based chemotherapy. This was done using univariate logistic regression and applying different inheritance models (dominant, recessive, and codominant), with the results of these analyses shown in [Table 4](#T4). We identified a protective correlation between the 6bp deletion of the *TYMS* 3\u2019UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients. **Additionally, the C/C genotype of the *ERCC2* rs13181 polymorphism was correlated with a lower risk of gastrointestinal disorders in our study population.**\"",
                "\"ERCC2 c.2251A>C (rs13181)  |  |  |  |  |\n| Codominant | A/A | 1.000 | -- | Ref. |\n| A/C | 0.152 | 0.007 \u2013 0.991 | 0.093 |  |\n| C/C | 0.100 | 0.004 \u2013 0.710 | 0.045* |  |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs13181",
                "variant_id": "PA166155343",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1695",
            "gene": "GSTP1",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Grouped hematological disorders: GSTP1 c.313A>G (rs1695) G allele carriers had a lower risk of hematological disorders. Dominant model (A/G+G/G vs A/A): OR=0.298, 95% CI 0.013\u20130.617, p=0.001. Recessive model (G/G vs A/A+A/G): OR=0.157, 95% CI 0.048\u20130.414, p=0.0005.",
              "Sentence": "Genotypes A/G + G/G are associated with decreased risk of hematological disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype A/A.",
              "Alleles": "A/G + G/G",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of hematological disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The G allele of the *GSTP1* rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy.\"",
                "\"GSTP1 c.313A>G (rs1695)  \n...\nHematological disorders  \n...\nDominant  \nA/A  \n1.000  \n--  \nRef.  \nA/G+G/G  \n0.298  \n0.013 \u2013 0.617  \n0.001*  \nRecessive  \nA/A+A/G  \n1.000  \n--  \nRef.  \nG/G  \n0.157  \n0.048 \u2013 0.414  \n0.0005*\"",
                "\"Overall, the evidence suggests that genotyping genes involved in the metabolism of 5-FU, L-OHP, and other commonly used drugs in CRC chemotherapy may provide valuable insight into the factors contributing to ADRs in CRC patients.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1695",
                "variant_id": "PA166154249",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1695",
            "gene": "GSTP1",
            "drug": "oxaliplatin",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "oxaliplatin",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Nervous system disorders (grouped) including neuropathy: GSTP1 c.313A>G (rs1695) G/G genotype associated with reduced risk. Codominant model: A/A vs G/G OR=0.098, 95% CI 0.011\u20130.570, p=0.015; recessive model (G/G vs A/A+A/G) OR=0.182, 95% CI 0.040\u20130.759, p=0.020. Individual ADR analysis: G allele was protective against neuropathy (OR\u22480.01, p=0.008; reported as OR=0.01, p=0.008 in Supplementary Table 3). Most neuropathy is attributable to oxaliplatin-containing regimens.",
              "Sentence": "Genotype G/G is associated with decreased risk of nervous system disorders including neuropathy in patients with advanced colorectal cancer treated with oxaliplatin-containing 5-fluorouracil-based chemotherapy as compared to genotypes A/A + A/G.",
              "Alleles": "G/G",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of nervous system disorders including neuropathy with",
              "Multiple drugs And/or": "and",
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A + A/G",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The G allele of the *GSTP1* rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ([Supplementary Table 3](#SM1), OR = 0.01, p-value = 0.008).\"",
                "\"Nervous system disorders |  |  |  |  |\n| GSTP1 c.313A>G (rs1695) |  |  |  |  |\n| Codominant | A/A | 1.000 | -- | Ref. |\n| A/G | 0.352 | 0.045 \u2013 1.906 | 0.251 |  |\n| G/G | 0.098 | 0.011 \u2013 0.570 | 0.015* |  |\n| Recessive | A/A+A/G | 1.000 | -- | Ref. |\n| G/G | 0.182 | 0.040 \u2013 0.759 | 0.020* |  |\"",
                "\"L-OHP is an alkylating agent primarily eliminated through glutathione conjugation, mediated by glutathione S-transferase (GST) enzymes ([Figure 2](#f2)). One of the most studied SNPs associated with CRC treatment-related ADR is *GSTP1* rs1695 (c.313A>G), which alters protein structure ([44](#B44)). Our findings indicate that the A allele is associated with an increased risk of hematological and nervous system ADR, aligning with previous studies ([45](#B45)).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1695",
                "variant_id": "PA166154249",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "oxaliplatin",
                "drug_id": "PA131285527",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs1695",
            "gene": "GSTP1",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Individual ADR analysis (ungrouped) showed a higher risk of mucositis (a gastrointestinal toxicity) in patients carrying the G allele of GSTP1 rs1695: OR=2.27, p=0.036. The abstract states the G allele increased mucositis risk (OR=2.27; p=0.036).",
              "Sentence": "Carriage of the G allele is associated with increased risk of mucositis in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to the A/A genotype.",
              "Alleles": "A/G + G/G",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of mucositis with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cAmong the 16 variants analyzed in 82 patients, key findings included: The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).\u201d",
                "\u201cThe G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping ([Supplementary Table 3](#SM1), OR = 0.01, p-value = 0.008). However, we observed a higher risk of mucositis in patients carrying this polymorphism ([Supplementary Table 3](#SM1), OR = 2.27, p-value = 0.036).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1695",
                "variant_id": "PA166154249",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1801265",
            "gene": "DPYD",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "rs1801265",
              "Gene": "DPYD",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "DPYD c.85T>C (rs1801265; DPYD*9A) C allele was linked to higher neuropathy risk. Supplementary Table 3: univariate logistic regression of individual ADR neuropathy showed, in a codominant model, T/C genotype OR=30.0, p=0.0049; in a dominant model (T/C + C/C vs T/T), OR=4.583, p=0.05. The abstract reports: C allele linked to higher neuropathy risk (OR=4.58; p=0.05).",
              "Sentence": "Genotypes T/C + C/C are associated with increased risk of neuropathy in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype T/T.",
              "Alleles": "T/C + C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of neuropathy with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\u201cFurther analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the *DPYD* rs1801265 polymorphism ([Supplementary Table 3](#SM1), codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05).\u201d",
                "\u201cFurther analysis of ungrouped ADRs indicated a higher risk of neuropathy in patients carrying the C allele of the *DPYD* rs1801265 polymorphism (Supplementary Table 3, codominant model T/C genotype OR = 30.0, p-value = 0.0049, dominant model OR = 4.583, p-value = 0.05). The C allele was identified as a risk factor for the development of neuropathies.\u201d",
                "\u201cThe C allele of *DPYD* (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1801265",
                "variant_id": "PA166153648",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs11479",
            "gene": "TYMP",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "rs11479",
              "Gene": "TYMP",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Grouped ADR category pain: TYMP c.1412C>T (rs11479) T allele associated with higher risk of pain. Univariate logistic regression, dominant model (C/T+T/T vs C/C): OR=5.860, 95% CI 1.381\u201331.420, p=0.027. The discussion notes a direct correlation between the T allele and increased risk of pain.",
              "Sentence": "Genotypes C/T + T/T are associated with increased risk of pain in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype C/C.",
              "Alleles": "C/T + T/T",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of pain with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients.",
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model).",
                "Within 5-FU pharmacokinetics, thymidate phosphorylase (TP) is a key enzyme responsible for initiating the activation of 5-FU into its active metabolite, which inhibits TS. Additionally, TP is crucial for the biotransformation of capecitabine (5-FU pro-drug). The *TYMP* c.1412C>T (rs11479) genetic variant, is a missense mutation that induces a structural change in the protein, affecting its catalytic activity. In this study it was observed that the T allele was associated with pain development."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11479",
                "variant_id": "PA166156029",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1128503",
            "gene": "ABCB1",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "rs1128503",
              "Gene": "ABCB1",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Grouped ADR pain: ABCB1 c.1236T>C (rs1128503) C/C genotype associated with higher pain risk. Univariate logistic regression, recessive model (C/C vs T/T+T/C): OR=4.200, 95% CI 1.038\u201319.256, p=0.049.",
              "Sentence": "Genotype C/C is associated with increased risk of pain in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotypes T/T + T/C.",
              "Alleles": "C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of pain with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T/T + T/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the *ABCB1* rs1128503 polymorphism exhibited a higher risk of pain.\"",
                "\"The next stage of analysis involved evaluating the correlation between the polymorphisms in the *TYMS*, *TYMP*, *DPYD*, *GSTP1*, *MTHFR*, *ERCC2*, and *ABC* genes and the risk of ADR of any severity during FU-based chemotherapy. This was done using univariate logistic regression and applying different inheritance models (dominant, recessive, and codominant), with the results of these analyses shown in [Table 4](#T4).\"",
                "\"Pain |  |  |  |  |\n| TYMP c.1412C>T (rs11479) |  |  |  |  |\n| Dominant | C/C | 1.000 | -- | Ref. |\n| C/T+T/T | 5.860 | 1.381 \u2013 31.420 | 0.027* |  |\n| ABCB1 c.1236T>C (rs1128503) |  |  |  |  |\n| Recessive | T/T+T/C | 1.000 | -- | Ref. |\n| C/C | 4.200 | 1.038 \u2013 19.256 | 0.049* |  |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1128503",
                "variant_id": "PA166157288",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1801131",
            "gene": "MTHFR",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 11,
              "Variant/Haplotypes": "rs1801131",
              "Gene": "MTHFR",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Grouped ADR pain: MTHFR c.1409A>C (rs1801131; likely 1298A>C) C allele associated with lower pain risk. Univariate logistic regression: codominant model A/A vs A/C OR=0.355, 95% CI 0.126\u20130.947, p=0.042; dominant model (A/C+C/C vs A/A) OR=0.375, 95% CI 0.137\u20130.976, p=0.048. Discussion: C allele correlated with lower risk of pain.",
              "Sentence": "Genotypes A/C + C/C are associated with decreased risk of pain in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype A/A.",
              "Alleles": "A/C + C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "risk of pain with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the *ABCB1* rs1128503 polymorphism exhibited a higher risk of pain. Conversely, the C allele of the *MTHFR* rs1801131 polymorphism was correlated with a lower risk of pain, but a higher risk of nervous system disorders in chemotherapy patients.\"",
                "\"For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model).\"",
                "\"For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1801131",
                "variant_id": "PA166153643",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1801131",
            "gene": "MTHFR",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 12,
              "Variant/Haplotypes": "rs1801131",
              "Gene": "MTHFR",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Grouped nervous system disorders: MTHFR c.1409A>C (rs1801131) C allele increased risk of nervous system ADR. Univariate logistic regression, dominant model (A/C+C/C vs A/A): OR=5.805, 95% CI 1.324\u201340.992, p=0.035. Discussion: C allele correlated with higher risk of nervous system disorders.",
              "Sentence": "Genotypes A/C + C/C are associated with increased risk of nervous system disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotype A/A.",
              "Alleles": "A/C + C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of nervous system disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the *ABCB1* rs1128503 polymorphism exhibited a higher risk of pain. Conversely, the C allele of the *MTHFR* rs1801131 polymorphism was correlated with a lower risk of pain, but a higher risk of nervous system disorders in chemotherapy patients.\"",
                "\"Nervous system disorders |  |  |  |  |\n| GSTP1 c.313A>G (rs1695) |  |  |  |  |\n| Codominant | A/A | 1.000 | -- | Ref. |\n| A/G | 0.352 | 0.045 \u2013 1.906 | 0.251 |  |\n| G/G | 0.098 | 0.011 \u2013 0.570 | 0.015* |  |\n| Recessive | A/A+A/G | 1.000 | -- | Ref. |\n| G/G | 0.182 | 0.040 \u2013 0.759 | 0.020* |  |\n| MTHFR c.1409A>C (rs1801131) |  |  |  |  |\n| Dominant | A/A | 1.000 | -- | Ref. |\n| A/C+C/C | 5.805 | 1.324 \u2013 40.992 | 0.035* |  |\"",
                "\"For 5-FU metabolites to effectively inhibit TS, the folate cycle must be functional, as it generates TS\u2019s secondary substrate. Without this substrate, TS is unable to bind FdUMP preventing its inhibitory activity ([Figure 1](#f1)). The MTHFR enzyme plays a crucial role in this process, as it catalyzes the conversion of 5,10-MTHF to 5-methyltetrahydrofolate (5-MTHF) ([40](#B40)). \u2026 In our study, the C allele was associated with an increased risk of nervous system ADR, yet it also acted as a protective factor against pain development.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1801131",
                "variant_id": "PA166153643",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs45445694",
            "gene": "TYMS",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "rs45445694",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Skin and subcutaneous tissue disorders (grouped): TYMS 5\u2019UTR TSER (rs45445694) 3R/3R genotype associated with increased risk. Recessive model (3R/3R vs 2R/2R + 2R/3R): OR=6.400, 95% CI 1.188\u201336.705, p=0.029. Abstract: 3R genotype is a risk factor for skin and subcutaneous tissue disorders (OR=6.40; p=0.029).",
              "Sentence": "Genotype 3R/3R is associated with increased risk of skin and subcutaneous tissue disorders in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to genotypes 2R/2R + 2R/3R.",
              "Alleles": "3R/3R",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of skin and subcutaneous tissue disorders with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "2R/2R + 2R/3R",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Among the 16 variants analyzed in 82 patients, key findings included: The G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036). The C allele of DPYD (rs1801265) was linked to a higher neuropathy risk (OR = 4.58; p = 0.05). The TYMS deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001). On the other hand, the 3R genotype of TYMS 5\u2019UTR (rs45445694) is associated as a risk factor for skin and subcutaneous tissue disorders (OR = 6.40; p = 0.029).",
                "Skin and subcutaneous tissue disorders |  |  |  |  |\n| TYMS 5'UTR 2R3R (rs45445694) |  |  |  |  |\n| Recessive | 2R/2R + 2R/3R | 1.000 | -- | Ref. |\n| 3R/3R | 6.400 | 1.188 \u2013 36.705 | 0.029* |",
                "Lastly, the 3R/3R genotype of the TYMS rs45445694 polymorphism was associated with an increased risk of skin and subcutaneous tissue disorders."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs45445694",
                "variant_id": "PA166155331",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs11479",
            "gene": "TYMP, ABCB1",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 14,
              "Variant/Haplotypes": "rs11479",
              "Gene": "TYMP, ABCB1",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Multivariate logistic regression model for ungrouped ADR anemia used TYMP rs11479 and ABCB1 rs1045642 (c.3435T>C) under recessive models. TYMP rs11479 T/T: \u03b2=3.168, OR=23.760, 95% CI 1.722\u2013986.648, p=0.038; ABCB1 rs1045642 T/T: \u03b2=\u22121.877, OR=0.153, 95% CI 0.007\u20130.975, p=0.093 (not statistically significant at 0.05). Model \u03c7\u00b2=7.22, p=0.027, pseudo-R\u00b2=0.145, accuracy 71.8%, sensitivity 0.231, AUC\u22480.71. The model indicates TYMP T/T genotype strongly increases risk of anemia in this treatment context.",
              "Sentence": "Genotype T/T of TYMP rs11479 in combination with ABCB1 rs1045642 contributes to an increased risk of anemia in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to non\u2013T/T genotypes.",
              "Alleles": "TYMP rs11479 T/T; ABCB1 rs1045642 T/T",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of anemia with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TYMP rs11479 C/C + C/T; ABCB1 rs1045642 C/C + C/T (implicitly non-recessive)",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Using the of *TYMP* rs11479 and *ABCB1* rs1044642 genetic polymorphisms, we generated the best predictive model for anemia (ungrouped ADR), applying a recessive inheritance model for both variants. The model is shown in [Table 5](#T5), and the corresponding ROC curve is displayed in [Figure 3](#f3).",
                "Table 5 Caption: Multivariate model of the correlation between the TYMP rs11479 and ABCB1 rs1044642 genotypes and the risk of anemia.",
                "Regarding multivariate models, only two models were successfully generated, one predicting anemia risk and another predicting pain risk. In the study by Deng et al., 2020, *DPYD* and *GSTP1* were identified has strong predictors of ADR, including anemia ([46](#B46)). In contrast, our anemia predictor model incorporated *ABCB1* and *TYMP* variants, which have not been previously associated with anemia risk. However, it is important to note that the *ABCB1* variant was not statistically significant within the model."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11479, rs1045642",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs1045642",
            "gene": "TYMP, ABCB1",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 14,
              "Variant/Haplotypes": "rs1045642",
              "Gene": "TYMP, ABCB1",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Multivariate logistic regression model for ungrouped ADR anemia used TYMP rs11479 and ABCB1 rs1045642 (c.3435T>C) under recessive models. TYMP rs11479 T/T: \u03b2=3.168, OR=23.760, 95% CI 1.722\u2013986.648, p=0.038; ABCB1 rs1045642 T/T: \u03b2=\u22121.877, OR=0.153, 95% CI 0.007\u20130.975, p=0.093 (not statistically significant at 0.05). Model \u03c7\u00b2=7.22, p=0.027, pseudo-R\u00b2=0.145, accuracy 71.8%, sensitivity 0.231, AUC\u22480.71. The model indicates TYMP T/T genotype strongly increases risk of anemia in this treatment context.",
              "Sentence": "Genotype T/T of TYMP rs11479 in combination with ABCB1 rs1045642 contributes to an increased risk of anemia in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to non\u2013T/T genotypes.",
              "Alleles": "TYMP rs11479 T/T; ABCB1 rs1045642 T/T",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of anemia with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TYMP rs11479 C/C + C/T; ABCB1 rs1045642 C/C + C/T (implicitly non-recessive)",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Using the of *TYMP* rs11479 and *ABCB1* rs1044642 genetic polymorphisms, we generated the best predictive model for anemia (ungrouped ADR), applying a recessive inheritance model for both variants. The model is shown in [Table 5](#T5), and the corresponding ROC curve is displayed in [Figure 3](#f3).",
                "Table 5 Caption: Multivariate model of the correlation between the TYMP rs11479 and ABCB1 rs1044642 genotypes and the risk of anemia.",
                "Regarding multivariate models, only two models were successfully generated, one predicting anemia risk and another predicting pain risk. In the study by Deng et al., 2020, *DPYD* and *GSTP1* were identified has strong predictors of ADR, including anemia ([46](#B46)). In contrast, our anemia predictor model incorporated *ABCB1* and *TYMP* variants, which have not been previously associated with anemia risk. However, it is important to note that the *ABCB1* variant was not statistically significant within the model."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11479, rs1045642",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs1801131",
            "gene": "MTHFR, ERCC2",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 15,
              "Variant/Haplotypes": "rs1801131",
              "Gene": "MTHFR, ERCC2",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Multivariate logistic regression model for grouped ADR pain combined MTHFR rs1801131 (dominant model A/C+C/C) and ERCC2 rs13181 (recessive model C/C). ERCC2 C/C: \u03b2=1.836, OR=6.272, 95% CI 1.285\u201340.539, p=0.034; MTHFR A/C+C/C: \u03b2=\u22121.836, OR=0.159, 95% CI 0.025\u20130.778, p=0.034. Model \u03c7\u00b2=9.161, p=0.01, pseudo-R\u00b2=0.185, accuracy 72.2%, sensitivity 0.625, AIC 0.8, AUC\u22480.75. ERCC2 C/C increases pain risk while MTHFR C allele (dominant) decreases pain risk.",
              "Sentence": "Genotype C/C of ERCC2 rs13181 together with genotypes A/A of MTHFR rs1801131 is associated with increased risk of pain in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to other genotype combinations.",
              "Alleles": "ERCC2 rs13181 C/C; MTHFR rs1801131 A/A vs A/C + C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of pain with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "ERCC2 rs13181 A/A + A/C; MTHFR rs1801131 A/C + C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).",
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).\n\nTable 6.\n\n| Variable |  | \u03b2 | SE | OR | CI (95%) | p-value |\n| --- | --- | --- | --- | --- | --- | --- |\n| Intercept |  | -2.663 | 1.45 | 0.026 | 0.003 - 0.999 | 0.066 |\n| ERCC2 (rs13181) C/C |  | 1.836 | 0.864 | 6.272 | 1.285 - 40.539 | 0.034* |\n| MTHFR (rs1801131) A/C+C/C |  | -1.836 | 0.864 | 0.159 | 0.025 - 0.778 | 0.034* |\n| Significancy and accuracy parameters of the model |  |  |  |  |  |  |\n| \u03c7\u00b2 | Degrees of freedom | Model\u2019s p-value | Pseudo-R2 | Accuracy | Sensitivity | AIC |\n| 9.161 | 2 | 0.01* | 0.185 | 72.222 | 0.625 | 0.8 |",
                "ROC curve of the multivariate model of risk of pain in CRC patients receiving FU-based chemotherapy."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1801131, rs13181",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs13181",
            "gene": "MTHFR, ERCC2",
            "drug": "5-fluorouracil-based chemotherapy",
            "annotation": {
              "Variant Annotation ID": 15,
              "Variant/Haplotypes": "rs13181",
              "Gene": "MTHFR, ERCC2",
              "Drug(s)": "5-fluorouracil-based chemotherapy",
              "PMID": 40786508,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Multivariate logistic regression model for grouped ADR pain combined MTHFR rs1801131 (dominant model A/C+C/C) and ERCC2 rs13181 (recessive model C/C). ERCC2 C/C: \u03b2=1.836, OR=6.272, 95% CI 1.285\u201340.539, p=0.034; MTHFR A/C+C/C: \u03b2=\u22121.836, OR=0.159, 95% CI 0.025\u20130.778, p=0.034. Model \u03c7\u00b2=9.161, p=0.01, pseudo-R\u00b2=0.185, accuracy 72.2%, sensitivity 0.625, AIC 0.8, AUC\u22480.75. ERCC2 C/C increases pain risk while MTHFR C allele (dominant) decreases pain risk.",
              "Sentence": "Genotype C/C of ERCC2 rs13181 together with genotypes A/A of MTHFR rs1801131 is associated with increased risk of pain in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy as compared to other genotype combinations.",
              "Alleles": "ERCC2 rs13181 C/C; MTHFR rs1801131 A/A vs A/C + C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of pain with",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Colorectal Neoplasms",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "ERCC2 rs13181 A/A + A/C; MTHFR rs1801131 A/C + C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).",
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).\n\nTable 6.\n\n| Variable |  | \u03b2 | SE | OR | CI (95%) | p-value |\n| --- | --- | --- | --- | --- | --- | --- |\n| Intercept |  | -2.663 | 1.45 | 0.026 | 0.003 - 0.999 | 0.066 |\n| ERCC2 (rs13181) C/C |  | 1.836 | 0.864 | 6.272 | 1.285 - 40.539 | 0.034* |\n| MTHFR (rs1801131) A/C+C/C |  | -1.836 | 0.864 | 0.159 | 0.025 - 0.778 | 0.034* |\n| Significancy and accuracy parameters of the model |  |  |  |  |  |  |\n| \u03c7\u00b2 | Degrees of freedom | Model\u2019s p-value | Pseudo-R2 | Accuracy | Sensitivity | AIC |\n| 9.161 | 2 | 0.01* | 0.185 | 72.222 | 0.625 | 0.8 |",
                "ROC curve of the multivariate model of risk of pain in CRC patients receiving FU-based chemotherapy."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1801131, rs13181",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil-based chemotherapy",
                "drug_id": null,
                "confidence": 0.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.8315946623682976,
      "total_samples": 5,
      "ground_truth_annotations": {
        "count": 5,
        "matched_count": 5,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.87860666513443,
            "annotation": {
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "FOLFOX, XELOX",
              "Phenotype Category": "Toxicity",
              "Alleles": "GG",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Mucositis",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "AA + AG"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1695",
                "prediction": "rs1695",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "GSTP1",
                "prediction": "GSTP1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "score": 0.9167992472648621,
                "match_status": "partial_match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "GG",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Mucositis",
                "prediction": "Side Effect:Mucositis",
                "score": 1.0,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA + AG",
                "prediction": "A/A",
                "score": 0.8692674040794373,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8833374798297882,
            "annotation": {
              "Variant/Haplotypes": "rs45445694",
              "Gene": "TYMS",
              "Drug(s)": "FOLFOX, XELOX",
              "Phenotype Category": "Toxicity",
              "Alleles": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs45445694",
                "prediction": "rs45445694",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "TYMS",
                "prediction": "TYMS",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "score": 0.9167992472648621,
                "match_status": "partial_match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Hand-foot syndrome, Side Effect:Exanthema, Side Effect:Drug Toxicity",
                "prediction": "Side Effect:Skin and subcutaneous tissue disorders",
                "score": 0.91657555103302,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8721978902816773,
            "annotation": {
              "Variant/Haplotypes": "rs1801265",
              "Gene": "DPYD",
              "Drug(s)": "FOLFOX, XELOX",
              "Phenotype Category": "Toxicity",
              "Alleles": "AG + GG",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Peripheral Nervous System Diseases",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "AA"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1801265",
                "prediction": "rs1801265",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "DPYD",
                "prediction": "DPYD",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "score": 0.9167992472648621,
                "match_status": "partial_match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "AG + GG",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Peripheral Nervous System Diseases",
                "prediction": "Side Effect:Neuropathy",
                "score": 0.9509705901145935,
                "match_status": "match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA",
                "prediction": "T/T",
                "score": 0.8542090654373169,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8739761233329773,
            "annotation": {
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "FOLFOX, XELOX",
              "Phenotype Category": "Toxicity",
              "Alleles": "GG",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "AA + AG"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs1695",
                "prediction": "rs1695",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "GSTP1",
                "prediction": "GSTP1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "score": 0.9167992472648621,
                "match_status": "partial_match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "GG",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
                "prediction": "Side Effect:Neuropathy",
                "score": 0.9262335300445557,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "AA + AG",
                "prediction": "A/A + A/G",
                "score": 0.8967284560203552,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.7822759807109833,
            "annotation": {
              "Variant/Haplotypes": "rs11280056",
              "Gene": "TYMS",
              "Drug(s)": "FOLFOX, XELOX",
              "Phenotype Category": "Toxicity",
              "Alleles": "TTA/TTA + TTA/TTAAAGTTA",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Phenotype": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": null
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs11280056",
                "prediction": "rs11280056",
                "score": 1.0,
                "match_status": "match"
              },
              "Gene": {
                "ground_truth": "TYMS",
                "prediction": "TYMS",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "FOLFOX, XELOX",
                "prediction": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "score": 0.9167992472648621,
                "match_status": "partial_match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "TTA/TTA + TTA/TTAAAGTTA",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "decreased",
                "prediction": "decreased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Peripheral Nervous System Diseases, Side Effect:Myelosuppression",
                "prediction": "Side Effect:Gastrointestinal disorders",
                "score": 0.9059605598449707,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": null,
                "prediction": "INS/INS",
                "score": 0.0,
                "match_status": "no_match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 9,
        "items": [
          {
            "variant": "rs1695",
            "gene": "GSTP1",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "G allele was protective against hematological disorders during 5-FU-based chemotherapy (dominant model A/G+G/G vs A/A OR=0.298, p=0.001; recessive G/G vs A/A+A/G OR=0.157, p=0.0005). Grouped hematological disorders included anemia and thrombocytopenia.",
              "Sentence": "rs1695 Is Associated with decreased risk of Side Effect:Hematological disorders when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Hematological disorders",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "\"The G allele of the *GSTP1* rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy.\"",
                "\"GSTP1 c.313A>G (rs1695) ... Hematological disorders ... Dominant | A/A | 1.000 | -- | Ref. | A/G+G/G | 0.298 | 0.013 \u2013 0.617 | 0.001* ... Recessive | A/A+A/G | 1.000 | -- | Ref. | G/G | 0.157 | 0.048 \u2013 0.414 | 0.0005*\"",
                "\"L-OHP is an alkylating agent primarily eliminated through glutathione conjugation, mediated by glutathione S-transferase (GST) enzymes ([Figure 2](#f2)). One of the most studied SNPs associated with CRC treatment-related ADR is *GSTP1* rs1695 (c.313A>G), which alters protein structure ([44](#B44)). Our findings indicate that the A allele is associated with an increased risk of hematological and nervous system ADR, aligning with previous studies ([45](#B45)).\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1695",
                "variant_id": "PA166154249",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1695",
            "gene": "GSTP1",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "rs1695",
              "Gene": "GSTP1",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "G allele was protective against nervous system disorders (grouped) during 5-FU-based chemotherapy; codominant model G/G vs A/A OR=0.098, p=0.015; recessive model G/G vs A/A+A/G OR=0.182, p=0.020.",
              "Sentence": "rs1695 Is Associated with decreased risk of Side Effect:Nervous system disorders when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Nervous system disorders",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A + A/G",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "4",
              "Citations": [
                "\u201cThe G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).\u201d",
                "\u201cThe G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping (Supplementary Table 3, OR = 0.01, p-value = 0.008).\u201d",
                "\u201cNervous system disorders |  |  |  |  |\n| GSTP1 c.313A>G (rs1695) |  |  |  |  |\n| Codominant | A/A | 1.000 | -- | Ref. |\n| A/G | 0.352 | 0.045 \u2013 1.906 | 0.251 |  |\n| G/G | 0.098 | 0.011 \u2013 0.570 | 0.015* |  |\n| Recessive | A/A+A/G | 1.000 | -- | Ref. |\n| G/G | 0.182 | 0.040 \u2013 0.759 | 0.020* |  |\u201d]}```}```\ufffc**Note**: I accidentally added some stray characters after the JSON object. The valid JSON response is everything up to and including the final `]}`. The extra ```}``` and symbols should be ignored. The correct JSON is:\n\n```json\n{\"citations\":[\"\u201cThe G allele of GSTP1 (rs1695) was protective against neuropathy (OR = 0.147; p = 0.012) but increased mucositis risk (OR = 2.27; p = 0.036).\u201d\",\"\u201cThe G allele of the GSTP1 rs1695 polymorphism was correlated with a lower risk of hematological and nervous system disorders in treated patients, including a reduced risk of neuropathy. This was observed through the analysis of individual ADR using univariate logistic regression without CTCAE v5.0 grouping (Supplementary Table 3, OR = 0.01, p-value = 0.008).\u201d\",\"\u201cNervous system disorders |  |  |  |  |\\n| GSTP1 c.313A>G (rs1695) |  |  |  |  |\\n| Codominant | A/A | 1.000 | -- | Ref. |\\n| A/G | 0.352 | 0.045 \u2013 1.906 | 0.251 |  |\\n| G/G | 0.098 | 0.011 \u2013 0.570 | 0.015* |  |\\n| Recessive | A/A+A/G | 1.000 | -- | Ref. |\\n| G/G | 0.182 | 0.040 \u2013 0.759 | 0.020* |  |\"]}\n```  "
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1695",
                "variant_id": "PA166154249",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs11280056",
            "gene": "TYMS",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "rs11280056",
              "Gene": "TYMS",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "6bp deletion in TYMS 3\u2019UTR (INS/DEL and DEL/DEL genotypes) conferred strong protection against hematological disorders during 5-FU-based chemotherapy; codominant INS/DEL OR=0.156, p=0.002; DEL/DEL OR=0.029, p=0.001; dominant INS/DEL+DEL/DEL OR=0.107, p<0.0001; recessive DEL/DEL OR=0.075, p=0.015. Also associated with lower risk of severe (grade III\u2013IV) hematological disorders (dominant model OR=0.098, p=0.005).",
              "Sentence": "rs11280056 Is Associated with decreased risk of Side Effect:Hematological disorders when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Hematological disorders",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "INS/INS",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "7",
              "Citations": [
                "\u201cAmong the 16 variants analyzed in 82 patients, key findings included: \u2026 The *TYMS* deletion genotype (rs11280056) conferred protection against hematological adverse reactions (OR = 0.029; p = 0.001).\u201d",
                "\u201cWe identified a protective correlation between the 6bp deletion of the *TYMS* 3\u2019UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients.\u201d",
                "\u201cWhen analyzing the risk of grouped ADR while considering only severe reactions (Grade III-IV), we found that only the *TYMS* 3\u2019UTR 6bp deletion (rs11280056) was the only polymorphism associated with a lower risk of severe hematological disorders (dominant model OR = 0,098, CI 95% 0.013 \u2013 0.441, p-value =0.005).\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11280056",
                "variant_id": "PA166180936",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs13181",
            "gene": "ERCC2",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "rs13181",
              "Gene": "ERCC2",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "C/C genotype of ERCC2 rs13181 associated with lower risk of gastrointestinal disorders during 5-FU-based chemotherapy; codominant model C/C vs A/A OR=0.100, 95% CI 0.004\u20130.710, p=0.045.",
              "Sentence": "rs13181 Is Associated with decreased risk of Side Effect:Gastrointestinal disorders when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Gastrointestinal disorders",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "A/A",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "8",
              "Citations": [
                "The next stage of analysis involved evaluating the correlation between the polymorphisms in the *TYMS*, *TYMP*, *DPYD*, *GSTP1*, *MTHFR*, *ERCC2*, and *ABC* genes and the risk of ADR of any severity during FU-based chemotherapy. This was done using univariate logistic regression and applying different inheritance models (dominant, recessive, and codominant), with the results of these analyses shown in [Table 4](#T4). We identified a protective correlation between the 6bp deletion of the *TYMS* 3\u2019UTR region (rs11280056) and a lower risk of gastrointestinal and hematological disorders in chemotherapy patients. Additionally, the C/C genotype of the *ERCC2* rs13181 polymorphism was correlated with a lower risk of gastrointestinal disorders in our study population.",
                "ERCC2 c.2251A>C (rs13181) |  |  |  |  |\n| Codominant | A/A | 1.000 | -- | Ref. |\n| A/C | 0.152 | 0.007 \u2013 0.991 | 0.093 |  |\n| C/C | 0.100 | 0.004 \u2013 0.710 | 0.045* |  |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs13181",
                "variant_id": "PA166155343",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs11479",
            "gene": "TYMP",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "rs11479",
              "Gene": "TYMP",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "T allele (C/T + T/T) of TYMP rs11479 associated with increased risk of pain during 5-FU-based chemotherapy; dominant model OR=5.860, 95% CI 1.381\u201331.420, p=0.027. In multivariate model with ABCB1 rs1045642, TYMP T/T genotype remained a strong predictor of anemia (OR=23.760, p=0.038).",
              "Sentence": "rs11479 Is Associated with increased risk of Side Effect:Pain when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Pain",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "C/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "9",
              "Citations": [
                "Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients.",
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model).",
                "Pain  |  |  |  |  |\n| TYMP c.1412C>T (rs11479) |  |  |  |  |\n| Dominant | C/C | 1.000 | -- | Ref. |\n| C/T+T/T | 5.860 | 1.381 \u2013 31.420 | 0.027* |  |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs11479",
                "variant_id": "PA166156029",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1128503",
            "gene": "ABCB1",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "rs1128503",
              "Gene": "ABCB1",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "C/C genotype of ABCB1 rs1128503 associated with higher risk of pain during 5-FU-based chemotherapy; recessive model C/C vs T/T+T/C OR=4.200, 95% CI 1.038\u201319.256, p=0.049.",
              "Sentence": "rs1128503 Is Associated with increased risk of Side Effect:Pain when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Pain",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "T/T + T/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "10",
              "Citations": [
                "\"Additionally, we found a direct correlation between the T allele of the *TYMP* rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the *ABCB1* rs1128503 polymorphism exhibited a higher risk of pain.\"",
                "\"ABCB1 c.1236T>C (rs1128503) |  |  |  |  |\n| Recessive | T/T+T/C | 1.000 | -- | Ref. |\n| C/C | 4.200 | 1.038 \u2013 19.256 | 0.049* |  |\"",
                "\"For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). ... ROC curve of the multivariate model of risk of pain in CRC patients receiving FU-based chemotherapy.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1128503",
                "variant_id": "PA166157288",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1801131",
            "gene": "MTHFR",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 11,
              "Variant/Haplotypes": "rs1801131",
              "Gene": "MTHFR",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "C allele (A/C + C/C) of MTHFR rs1801131 was protective against pain (dominant A/C+C/C vs A/A OR=0.375, 95% CI 0.137\u20130.976, p=0.048) but increased risk of nervous system disorders (dominant model A/C+C/C vs A/A OR=5.805, 95% CI 1.324\u201340.992, p=0.035).",
              "Sentence": "rs1801131 Is Associated with decreased risk of Side Effect:Pain and increased risk of Side Effect:Nervous system disorders when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": null,
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Pain, Side Effect:Nervous system disorders",
              "Multiple phenotypes And/or": "and",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Alleles(s) or Genotype(s)": null,
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "11",
              "Citations": [
                "\"MTHFR c.1409A>C (rs1801131)  |  |  |  |  |\n| Codominant | A/A | 1.000 | -- | Ref. |\n| A/C | 0.355 | 0.126 \u2013 0.947 | 0.042* |  |\n| C/C | 0.750 | 0.028 \u2013 19.827 | 0.842 |  |\n| Dominant | A/A | 1.000 | -- | Ref. |\n| A/C+C/C | 0.375 | 0.137 \u2013 0.976 | 0.048* |  |\"",
                "\"Additionally, we found a direct correlation between the T allele of the TYMP rs11479 polymorphism and an increased risk of pain in chemotherapy patients. Similarly, patients carrying the C/C genotype of the ABCB1 rs1128503 polymorphism exhibited a higher risk of pain. Conversely, the C allele of the MTHFR rs1801131 polymorphism was correlated with a lower risk of pain, but a higher risk of nervous system disorders in chemotherapy patients.\"",
                "\"MTHFR c.1409A>C (rs1801131)  |  |  |  |  |\n| Dominant | A/A | 1.000 | -- | Ref. |\n| A/C+C/C | 5.805 | 1.324 \u2013 40.992 | 0.035* |  |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1801131",
                "variant_id": "PA166153643",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs1045642",
            "gene": "ABCB1",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "rs1045642",
              "Gene": "ABCB1",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "In a multivariate logistic regression model for anemia risk, ABCB1 rs1045642 T/T genotype showed an OR=0.153, 95% CI 0.007\u20130.975, p=0.093 (not individually significant), while TYMP rs11479 T/T was significant. Overall model p=0.027 with accuracy 71.8% and AUC=0.71; model predicts risk of anemia during 5-FU-based chemotherapy.",
              "Sentence": "rs1045642 Is Associated with decreased risk of Side Effect:Anemia when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer, according to a multivariate model including TYMP rs11479.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Anemia",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Alleles(s) or Genotype(s)": "C/C + C/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "13",
              "Citations": [
                "\"Using the of *TYMP* rs11479 and *ABCB1* rs1044642 genetic polymorphisms, we generated the best predictive model for anemia (ungrouped ADR), applying a recessive inheritance model for both variants. The model is shown in [Table 5](#T5), and the corresponding ROC curve is displayed in [Figure 3](#f3).\"",
                "\"Table 5 Caption: Multivariate model of the correlation between the TYMP rs11479 and ABCB1 rs1044642 genotypes and the risk of anemia.\"",
                "\"ABCB1 (rs1045642) T/T  -1.877  1.119  0.153  0.007 - 0.975  0.093\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs1045642",
                "variant_id": "PA166157284",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          },
          {
            "variant": "rs13181",
            "gene": "ERCC2",
            "drug": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
            "annotation": {
              "Variant Annotation ID": 14,
              "Variant/Haplotypes": "rs13181",
              "Gene": "ERCC2",
              "Drug(s)": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
              "PMID": "40786508",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "In multivariate model for pain risk, ERCC2 rs13181 C/C genotype was associated with increased risk of pain (OR=6.272, 95% CI 1.285\u201340.539, p=0.034), whereas MTHFR rs1801131 A/C+C/C was protective. Model p=0.01, accuracy 72.2%, AUC=0.75.",
              "Sentence": "rs13181 Is Associated with increased risk of Side Effect:Pain when treated with 5-fluorouracil, oxaliplatin, irinotecan, capecitabine in people with Disease:Colorectal cancer, according to a multivariate model including MTHFR rs1801131.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Pain",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "and",
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Colorectal cancer",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Alleles(s) or Genotype(s)": "A/A + A/C",
              "Comparison Metabolizer types": null,
              "PMID_norm": "40786508",
              "Variant Annotation ID_norm": "14",
              "Citations": [
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).",
                "Table 6 Caption: Multivariate model of the correlation between the MTHFR rs180131 and ERCC2 rs13181 genotypes and the risk of pain..",
                "For the ADR category pain, we obtained the best multivariate risk model with the *MTHFR* rs180131 (dominant model) and the *ERCC2* rs13181 polymorphism (recessive model). The resulting model and the model\u2019s ROC curve are shown in [Table 6](#T6) and [Figure 4](#f4).\n\n| Variable |  | \u03b2 | SE | OR | CI (95%) | p-value |\n| --- | --- | --- | --- | --- | --- | --- |\n| Intercept |  | -2.663 | 1.45 | 0.026 | 0.003 - 0.999 | 0.066 |\n| ERCC2 (rs13181) C/C |  | 1.836 | 0.864 | 6.272 | 1.285 - 40.539 | 0.034* |\n| MTHFR (rs1801131) A/C+C/C |  | -1.836 | 0.864 | 0.159 | 0.025 - 0.778 | 0.034* |\n| Significancy and accuracy parameters of the model |  |  |  |  |  |  |\n| \u03c7\u00b2 | Degrees of freedom | Model\u2019s p-value | Pseudo-R2 | Accuracy | Sensitivity | AIC |\n| 9.161 | 2 | 0.01* | 0.185 | 72.222 | 0.625 | 0.8 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs13181",
                "variant_id": "PA166155343",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "5-fluorouracil, oxaliplatin, irinotecan, capecitabine",
                "drug_id": null,
                "confidence": 0.0
              }
            }
          }
        ]
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.6520024249288772,
      "total_samples": 6,
      "ground_truth_annotations": {
        "count": 6,
        "matched_count": 6,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.5830940148409676,
            "annotation": {
              "Study Parameters ID": 1454223659,
              "Variant Annotation ID": 1454223625,
              "Study Type": null,
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "Skin and subcutaneous tissue disorders (recessive)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.029",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454223659,
                "prediction": 16,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223625,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Skin and subcutaneous tissue disorders (recessive)",
                "prediction": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 5\u2019UTR TSER 2R/3R (rs45445694) with skin and subcutaneous tissue disorders (any grade) under a recessive model, genotype 3R/3R vs 2R/2R + 2R/3R",
                "score": 0.9125982522964478,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.029",
                "prediction": "= 0.029",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 6.4,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.188,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 36.705,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5815296488649705,
            "annotation": {
              "Study Parameters ID": 1454223622,
              "Variant Annotation ID": 1454223640,
              "Study Type": null,
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "Hematological disorders",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.0005",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454223622,
                "prediction": 10,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223640,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Hematological disorders",
                "prediction": "Chilean advanced colorectal cancer patients treated with 5-FU/oxaliplatin-based regimens; association of GSTP1 c.313A>G (rs1695) with hematological disorders (any grade) under a recessive model, genotype G/G vs A/A + A/G",
                "score": 0.8860040307044983,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.0005",
                "prediction": "= 0.0005",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.157,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.048,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.414,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5807715408942279,
            "annotation": {
              "Study Parameters ID": 1454223621,
              "Variant Annotation ID": 1454223640,
              "Study Type": null,
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "neuropathy",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.02",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454223621,
                "prediction": 19,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223640,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "neuropathy",
                "prediction": "Chilean advanced colorectal cancer patients treated with oxaliplatin-containing regimens; association of GSTP1 c.313A>G (rs1695) with nervous system disorders (any grade) under a recessive model, genotype G/G vs A/A + A/G",
                "score": 0.8731161952018738,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.02",
                "prediction": "= 0.020",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.182,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.04,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.759,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5773488184984992,
            "annotation": {
              "Study Parameters ID": 1454223606,
              "Variant Annotation ID": 1454223600,
              "Study Type": null,
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "neuropathy",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.05",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454223606,
                "prediction": 12,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223600,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "neuropathy",
                "prediction": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of ABCB1 c.1236T>C (rs1128503) with pain (any grade) under a recessive model, genotype C/C vs T/T + T/C",
                "score": 0.8649299144744873,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.05",
                "prediction": "= 0.049",
                "score": 0.95,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 4.2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.038,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 19.256,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5767052566303926,
            "annotation": {
              "Study Parameters ID": 1454223681,
              "Variant Annotation ID": 1454223701,
              "Study Type": null,
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "Mucositis",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.036",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454223681,
                "prediction": 20,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223701,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Mucositis",
                "prediction": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of MTHFR c.1409A>C (rs1801131) with nervous system disorders (any grade) under a dominant model, genotypes A/C + C/C vs A/A",
                "score": 0.8539893627166748,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.036",
                "prediction": "= 0.035",
                "score": 0.95,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 5.805,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 1.324,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 40.992,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5523282640120563,
            "annotation": {
              "Study Parameters ID": 1454223623,
              "Variant Annotation ID": 1454223652,
              "Study Type": null,
              "Study Cases": 82.0,
              "Study Controls": null,
              "Characteristics": "Hematological disorders",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.005",
              "Ratio Stat Type": null,
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "Latino"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1454223623,
                "prediction": 6,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1454223652,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "case/control",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 82.0,
                "prediction": 82,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Hematological disorders",
                "prediction": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 3\u2019UTR 6bp ins-del (rs11280056) with hematological disorders (any grade) under a codominant model, genotype DEL/DEL vs INS/INS",
                "score": 0.889580488204956,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.005",
                "prediction": "= 0.001",
                "score": 0.5,
                "match_status": "partial_match"
              },
              "Ratio Stat Type": {
                "ground_truth": null,
                "prediction": "OR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.029,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.004,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 0.182,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "Latino",
                "prediction": "Latino",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 18,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 1,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 3\u2019UTR 6bp ins-del (rs11280056) with gastrointestinal disorders (any grade) under a codominant model, genotype INS/DEL vs INS/INS",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.093",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.152,
              "Confidence Interval Start": 0.007,
              "Confidence Interval Stop": 0.991,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 2,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 3\u2019UTR 6bp ins-del (rs11280056) with gastrointestinal disorders (any grade) under a codominant model, genotype DEL/DEL vs INS/INS",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.045",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.1,
              "Confidence Interval Start": 0.004,
              "Confidence Interval Stop": 0.71,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 3,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of ERCC2 c.2251A>C (rs13181) with gastrointestinal disorders (any grade) under a codominant model, genotype A/C vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.093",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.152,
              "Confidence Interval Start": 0.007,
              "Confidence Interval Stop": 0.991,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 4,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of ERCC2 c.2251A>C (rs13181) with gastrointestinal disorders (any grade) under a codominant model, genotype C/C vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.045",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.1,
              "Confidence Interval Start": 0.004,
              "Confidence Interval Stop": 0.71,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 3\u2019UTR 6bp ins-del (rs11280056) with hematological disorders (any grade) under a codominant model, genotype INS/DEL vs INS/INS",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.002",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.156,
              "Confidence Interval Start": 0.044,
              "Confidence Interval Stop": 0.498,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 3\u2019UTR 6bp ins-del (rs11280056) with hematological disorders (any grade) under a dominant model, genotypes INS/DEL + DEL/DEL vs INS/INS",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.107,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 0.303,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 8,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMS 3\u2019UTR 6bp ins-del (rs11280056) with hematological disorders (any grade) under a recessive model, genotype DEL/DEL vs INS/INS + INS/DEL",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.015",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.075,
              "Confidence Interval Start": 0.004,
              "Confidence Interval Stop": 0.421,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 9,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU/oxaliplatin-based regimens; association of GSTP1 c.313A>G (rs1695) with hematological disorders (any grade) under a dominant model, genotypes A/G + G/G vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.298,
              "Confidence Interval Start": 0.013,
              "Confidence Interval Stop": 0.617,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 11,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of TYMP c.1412C>T (rs11479) with pain (any grade) under a dominant model, genotypes C/T + T/T vs C/C",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.027",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 5.86,
              "Confidence Interval Start": 1.381,
              "Confidence Interval Stop": 31.42,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 13,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of MTHFR c.1409A>C (rs1801131) with pain (any grade) under a codominant model, genotype A/C vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.042",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.355,
              "Confidence Interval Start": 0.126,
              "Confidence Interval Stop": 0.947,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 14,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of MTHFR c.1409A>C (rs1801131) with pain (any grade) under a codominant model, genotype C/C vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.842",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.75,
              "Confidence Interval Start": 0.028,
              "Confidence Interval Stop": 19.827,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 15,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; association of MTHFR c.1409A>C (rs1801131) with pain (any grade) under a dominant model, genotypes A/C + C/C vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.048",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.375,
              "Confidence Interval Start": 0.137,
              "Confidence Interval Stop": 0.976,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 17,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with oxaliplatin-containing regimens; association of GSTP1 c.313A>G (rs1695) with nervous system disorders (any grade) under a codominant model, genotype A/G vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.251",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.352,
              "Confidence Interval Start": 0.045,
              "Confidence Interval Stop": 1.906,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 18,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with oxaliplatin-containing regimens; association of GSTP1 c.313A>G (rs1695) with nervous system disorders (any grade) under a codominant model, genotype G/G vs A/A",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.015",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.098,
              "Confidence Interval Start": 0.011,
              "Confidence Interval Stop": 0.57,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 21,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; multivariate logistic model for anemia including TYMP rs11479 and ABCB1 rs1045642 (recessive inheritance for both), effect of ABCB1 rs1045642 T/T vs other genotypes on risk of anemia",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.093",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.153,
              "Confidence Interval Start": 0.007,
              "Confidence Interval Stop": 0.975,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 22,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; multivariate logistic model for anemia including TYMP rs11479 and ABCB1 rs1045642 (recessive inheritance for both), effect of TYMP rs11479 T/T vs other genotypes on risk of anemia",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.038",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 23.76,
              "Confidence Interval Start": 1.722,
              "Confidence Interval Stop": 986.648,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 23,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; multivariate logistic model for pain including ERCC2 rs13181 (recessive) and MTHFR rs1801131 (dominant), effect of ERCC2 rs13181 C/C vs other genotypes on risk of pain",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.034",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 6.272,
              "Confidence Interval Start": 1.285,
              "Confidence Interval Stop": 40.539,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 24,
              "Variant Annotation ID": null,
              "Study Type": "case/control",
              "Study Cases": 82,
              "Study Controls": null,
              "Characteristics": "Chilean advanced colorectal cancer patients treated with 5-FU-based chemotherapy; multivariate logistic model for pain including ERCC2 rs13181 (recessive) and MTHFR rs1801131 (dominant), effect of MTHFR rs1801131 A/C + C/C vs A/A on risk of pain",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.034",
              "Ratio Stat Type": "OR",
              "Ratio Stat": 0.159,
              "Confidence Interval Start": 0.025,
              "Confidence Interval Stop": 0.778,
              "Biogeographical Groups": "Latino",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}